Comparing rivaroxaban and enoxaparin for preventing blood clots in obese patients undergoing weight loss surgery
Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Morbidly Obese Patients Undergoing Bariatric Surgery: An open_label Randomized Controlled Trial
This study tests whether the blood thinner rivaroxaban works better than enoxaparin to prevent blood clots in obese patients having weight loss surgery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 162 (estimated) |
| Ages | 20 Years to 60 Years |
| Sex | All |
| Sponsor | Alexandria University Academic / other |
| Locations | 1 site (Alexandria) |
| Trial ID | NCT06689241 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of rivaroxaban compared to enoxaparin for the prevention of venous thromboembolism (VTE) in morbidly obese patients who are candidates for bariatric surgery. The study is an open-label randomized controlled trial that aims to determine which medication is more effective in reducing the risk of post-operative blood clots. Given the rising prevalence of obesity and the associated risks of VTE, this research addresses a critical public health issue. Participants will be monitored for VTE incidence following their surgical procedures to assess the outcomes of each treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 20-60 years with a BMI between 35-50 kg/m² who are classified as ASA physical status class I to III.
Not a fit: Patients with severe cardiac disorders, chronic renal failure, liver cirrhosis, or major psychological disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prophylactic strategies for preventing life-threatening blood clots in obese patients undergoing bariatric surgery.
How similar studies have performed: Other studies have explored the use of anticoagulants for VTE prevention in surgical patients, but this specific comparison of rivaroxaban and enoxaparin in the context of bariatric surgery is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: 20-60 years, both sexes. * ASA physical status class I to III. * BMI 35-50 kg/m² Exclusion Criteria: * Severe cardiac disorder * chronic renal failure * liver cirrhosis * major psychological disorder
Where this trial is running
Alexandria
- Alexandria University — Alexandria, Egypt (Recruiting)
Study contacts
- Principal investigator: sarah m elgamal, MD — Alexandria University
- Study coordinator: sarah m elgamal, MD
- Email: sarahelgamal1990@yahoo.com
- Phone: 01005496440
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.